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Molecular modelingBitter taste receptors (T2Rs) belong to the superfamily of G protein-coupled receptors (GPCRs). T2Rs are
chemosensory receptors with important therapeutic potential. In humans, bitter taste is perceived by 25 T2Rs,
which are distinct from the well-studied Class A GPCRs. The activation mechanism of T2Rs is poorly understood
and none of the structure–function studies are focused on the role of the important third intracellular loop (ICL3).
T2Rs have a unique signature sequence at the cytoplasmic end of ﬁfth transmembrane helix (TM5), a highly
conserved LxxSL motif. Here, we pursue an alanine scan mutagenesis of the ICL3 of T2R4 and characterize the
functionality of 23 alanine mutants. We identify four mutants, H214A, Q216A, V234A and M237A, that exhibit
constitutive activity. To our surprise, the H214A mutant showed very high constitutive activity over wild
type T2R4. Interestingly, His214 is highly conserved (96%) in T2Rs and is present two amino acids below
the LxxSL motif in TM5. Molecular modeling shows a dynamic network of interactions involving residues in
TM5–ICL3–TM6 that restrain the movement of the helices. Changes in this network, as in the case of H214A,
Q216A, V234A and M237A mutants, cause the receptor to adopt an active conformation. The conserved LxxSL
motif in TM5 performs both structural and functional roles in this process. These results provide insight into the
activationmechanismof T2Rs, and emphasize the unique functional role of ICL3 evenwithin theGPCR subfamilies.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Humans can sense ﬁve basic tastes. Among these, sweet, umami and
bitter tastes are sensed by chemosensory receptors that belong to the G
protein-coupled receptor (GPCR) superfamily [1,2]. Sweet taste signals
are transduced by a heterodimer of T1R2 and T1R3, while the T1R1
and T1R3 heterodimer codes for the umami taste [1,3,4]. The three
receptor subunits (T1Rs), T1R1, T1R2 and T1R3, that code for sweet
and umami tastes belong to the class C GPCR family [2]. Class C GPCRs,
which include the metabotropic receptors, are characterized by a large
N-terminal domain, also known as the venus ﬂytrap (VFT), that forms
the primary (orthosteric) ligand binding site [2]. In contrast, the 25
bitter taste receptors (T2Rs) in humans have a short N-terminus [5,6]
and the ligand binds within the transmembrane (TM) domain [7,8].
The classiﬁcation of T2Rs within the GPCR superfamily is unclear with
some grouping them with frizzled receptors (FZD) [2], whereas others
place them separately [9]. However, the International Union of Basic
and Clinical Pharmacology (IUPHAR) list FZD as a separate GPCR family,
Class F or Frizzled, and this class does not include T2Rs [10]. Amino acid
sequence analysis of T2Rs showed that the conserved motifs such as
the D/ERY in TM3 and CWxP in TM6 are absent in T2Rs [11]. Mutationaliology, 780 Bannatyne Avenue,
ada. Tel.: +1 204 789 3539;
P. Chelikani).
ights reserved.studies of the highly conserved residues in the TM domain of T2Rs sug-
gest that these receptors might have a unique activation mechanism
compared to other classes of the GPCR superfamily [11,12].
Recently, we identiﬁed a conserved LxxSL motif in TM5 of T2Rs.
Mutational and molecular modeling analysis of this motif suggested
that it performs a structural role by stabilizing the helical conformation
of TM5 at the cytoplasmic end [11]. However, the LxxSLmotif is present
very close to the third intracellular loop (ICL3) and role of this loop in
T2R activation has not been studied thus far. ICL3was found to perform
different roles in different GPCR classes. For example in Ste2p, a yeast
GPCR, disulﬁde cross-linking experiments show that the cytoplasmic
ends of TM5 and TM6 that ﬂank ICL3 undergo conformational changes
upon ligand binding, whereas the center of the ICL3 loop does not [13].
In neuropeptide Y1 receptor (NPY1), ICL3 constrains the inactive state
of the receptor, and mutations in ICL3 lead to an agonist-independent
or basal or constitutive activity [14]. In contrast, a recent alanine scan
mutagenesis of ICL3 in the melanocortin-3 receptor (MC3R) showed
that ICL3 is important for ligand binding and signaling, but none of the
mutants displayed constitutive activity [15].
In this report,we have examined themolecular determinants in ICL3
which are required for bitter taste receptor activation and signaling. In
addition, we studied the interactions between the conserved LxxSL
motif and ICL3 in T2Rs. To elucidate this,we performed alanine scanmu-
tagenesis of ICL3 and functionally characterized 23 alanine mutants of
T2R4. Our results, which are based on site-directed mutagenesis, phar-
macological characterization of the mutants and molecular modeling
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(CAMs) in ICL3, with constitutive activity ranging from 2 to 10 fold
over wild type T2R4. Taken together, our results showed that the
cytoplasmic ends of TM5 and TM6 played an important role in T2R
activation, and ICL3 was involved in restraining T2Rs in an inactive
conformation.
2. Materials and methods
2.1. Materials
Calcium sensitive dye Fluo-4NW and cell culture media were pur-
chased from Invitrogen (Carlsbad, CA, USA). IP3 kit was from DiscoveRx
(Fremont, CA, USA). Fetal bovine serum (FBS), quinine, denatonium
benzoate, colchicine, yohimbine and common chemicals were pur-
chased from Sigma. The Gα16-gust44 chimera was a gift from
Dr. Takashi Ueda, Nagoya City University, Japan.
2.2. Molecular biology
The synthetic and N-terminal FLAG tagged TAS2R4 gene in the
mammalian expression vector pcDNA3.1 (Invitrogen) was described
before [12]. Alanine mutants were introduced into this gene using a
commercial service (GenScript Inc., USA). The wild type and mutant
TAS2R4 genes in pcDNA3.1 were transiently co-transfected along with
Gα16-gust44 chimera in HEK293T cells using lipofectamine 2000
(Invitrogen) as described previously [12].
2.3. Functional assays
Cell surface ELISA, calciummobilization assays, IP3 assays, and phar-
macological characterization of CAMswere performed according to pre-
viously published protocols [11,12,16].Fig. 1. Two-dimensional representation of the T2R4 amino acid sequence with FLAG-tag a
N-terminus, three extracellular loops (ECLs) and three intracellular loops (ICLs), and a cy
broken rings. The constitutively active mutants identiﬁed in this study are represented in2.4. Molecular modeling
The inactive and CAM models of T2R4 were built by homology
modeling as described before [12]. The models were minimized using
the steepest descent and conjugate gradient algorithms. MD simula-
tions of 10 ns were carried out with time-step of 2 fs, collecting trajec-
tory data every 500 ps. Simulationswere carried out using SYBYL X v2.1
modeling suite (Tripos Inc., USA).
3. Results
Structure–function analysis of T2Rs revealed unique signature resi-
dues in TM helices which are distinct from Class A GPCRs [11,12]. Our
previous structure–function studies on T2R4 targeted the N-terminus
and TM regions that play a role in receptor expression and activation
[12,17]. The intracellular region of T2R4 consists of 87 amino acids
which includes four alanines. In this report, using an N-terminal FLAG
tagged T2R4 (WT-T2R4) as the base receptor, the entire T2R4–ICL3
region consisting of 23 amino acids was replaced with alanines and
the mutants were characterized biochemically (Fig. 1).
3.1. Functional characterization
The natural alkaloid, quinine, acts as an agonist and activates T2R4
in a concentration dependent manner [12,18]. It is one of the well-
characterized agonists of T2R4 and has been used in this study. Taste
sensory analysis of a few bitter compounds has reported quinine as
the most intense bitter compound [11]. The 23 alanine mutants in
ICL3 of T2R4 displayed varied levels of calciummobilization upon stim-
ulation with quinine (Table 1). Only 14 of the 23 ICL3 alanine mutants
displayed quinine induced signaling in a concentration dependentman-
ner (Table 1). Three ICL3mutants, Q216A, T230A andV234A, showed an
increase in agonist induced response; however, their response was nott the N-terminus. The receptor consists of seven transmembrane (TM) helices, a short
toplasmic tail. The 23 ICL3 residues mutated to alanine in this study are displayed in
gray circles.
Table 1
Pharmacological characterization of the T2R4 alaninemutants. Functional characterization
of themutantswas pursued bymeasuring intracellular calciummobilized after stimulating
with different concentrations of agonist, quinine. Cell surface expression was determined
by ELISA.a
Mutant EC50 (μM) EC50 mutant/EC50
wild type
Cell surface
expression (%)
T2R4 997 ± 416 1.0 100 ± 3
R213A ND 133 ± 2
H214A 1345 ± 553 1.30 102 ± 8
I215A 2043 ± 1215 2.05 78 ± 1
Q216A NS 133 ± 20
K217A 1599 ± 1148 1.59 101 ± 21
M218A 1133 ± 512 1.13 121 ± 4
Q219A ND 109 ± 12
K220A ND 112 ± 29
N221A 1432 ± 674 1.43 118 ± 38
T223A 1339 1.34 106 ± 2
G224A 1638 ± 820 1.62 111 ± 36
F225A 1946 ± 656 1.95 105 ± 3
W226A 1213 ± 249 1.21 115 ± 10
N227A 1509 ± 977 1.51 99 ± 15
P228A 2756 ± 1308 2.75 100 ± 25
Q229A ND 101 ± 13
T230A NS 107 ± 47
E231A ND 110 ± 6
H233A ND 145 ± 12
V234A NS 107 ± 15
G235A 890 ± 452 0.89 139 ± 20
M237A 832 ± 567 0.83 106 ± 14
K238A 1822 ± 1170 1.82 143 ± 24
a Intracellular loop 3 (ICL3). ND — not detected, no signiﬁcant calcium mobilization
detected; NS— not saturated, quinine concentration dependent increase in calciummobi-
lization not observed.
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Concentrations higher than 5 mM resulted in signiﬁcant increase in
non-speciﬁc calcium mobilization in cells, expressing the WT-T2R4 or
mutants (data not shown). The R213A, Q219A, K220A, Q229A, E231A
and H233A mutants, upon stimulation with quinine, showed no de-
tectable or statistically signiﬁcant increase in intracellular calcium mo-
bilization when compared to mock transfected cells. Fig. 2 shows
representative calcium traces for select mutants and mock transfected
cells stimulated with a saturating concentration of 2.5 mM quinine.
Interestingly, I215A, F225A and P228A displayed altered receptor acti-
vation and/or defective ligand binding, as shown by a 2-fold increase in
EC50 mutant/wild type ratio (Table 1). For these three mutants, signal
was saturated at only the highest quinine concentration of 5 mM (one
saturating data point), and their EC50 values were calculated by non-
linear regression analysis using PRISM software version 4.03 (GraphPad
Software Inc., San Diego, CA). The threshold values (deﬁned as theFig. 2. Representative calcium traces for HEK293T cells transiently transfected with T2R4 and s
with 2.5 mM quinine (top panel) or assay buffer (lower panel). The calcium mobilized (RFUs
(Invitrogen), and ﬂuorescence measured using Flex Station III microplate reader as described blowest quinine concentration at which a speciﬁc calcium signal was
observed) for these mutants were 550 μM, 645 μM and 850 μM respec-
tively, compared to 200 μM for WT-T2R4. Cell surface ELISA revealed
that all the ICL3mutants were expressed on the surfacewith expression
levels ranging from 80% to 140% of WT-T2R4.
3.2. Identiﬁcation and characterization of CAMs in T2R4-ICL3
To obtain insights into the role of intracellular residues in T2R acti-
vation, we characterized the agonist-independent (basal) activity of
WT-T2R4 and all the 23 alanine mutants. Basal Ca2+ levels of WT-T2R4
and the mutants corrected for cell surface expression were measured
to assess the agonist-independent activity (Fig. 3). Mutants R213A,
H214A, Q216A, N227A, V234A and M237A showed statistically signiﬁ-
cant increased basal signaling (Fig. 3A). Since H214A shows the highest
basal activity in terms of calcium mobilized among the 23 alanine re-
placements, this mutant was selected for further study. To obtain direct
evidence of the constitutive activity of H214A, we measured the basal
IP3 of WT-T2R4 and H214A mutant (Fig. 3B). A standard graph was
constructed using different concentrations of IP3 provided by themanu-
facturer, and this graphwas used to calculate the amount of IP3 released
by the wild type and mutant receptor, and as described before [16].
IP3 levels of both receptors were measured by stimulating them with
buffer (agonist independent or basal) and these values were normalized
to cell surface expression of WT-T2R4 and H214A. When compared to
WT-T2R4, a 3-fold increasewas observed in agonist independent activity
of H214A, and the signiﬁcant p value was less than 0.01 (Fig. 3B).
The effect of receptor density on Ca2+ mobilization was calculated
from slope of expression vs. basal activity for the six mutants that
showed high basal signaling and compared to WT-T2R4. The results
based on the slope values showed that only H214A, Q216A, V234A
andM237Amutants exhibited a true CAM phenotype, with constitutive
activity ranging from 2 to 10 fold over WT-T2R4 (Fig. 3C). The H214A
mutant present at the TM5–ICL3 interface displayed the highest consti-
tutive activity. Interestingly, His214 is present in 24 of the 25 human
T2Rs (96% sequence conserved).
3.3. Analysis of molecular models
To interpret the effect of ICL3 CAMs on T2R4 structure and function,
we built homology models of the inactive WT-T2R4, a constitutively
active T2R4 and CAMs using rhodopsin inactive (PDB ID: 1U19) and
CAM (PDB ID: 2X72) crystal structures as templates. The four CAMs
in ICL3 identiﬁed in this study are present at the amino and carboxyl-
terminus of T2R4-ICL3. Through an intricate network that involves
side-chain and backbone interactions, His214, Gln216, Val234 and
Met237 interact with the highly conserved LxxSL motif on TM5 (Fig. 4elect mutants. The mock transfected (pcDNA) control is shown. The cells were stimulated
or Relative Fluorescence Units) was detected using the calcium sensitive dye Fluo 4NW
efore [12].
Fig. 3. A. Pharmacological characterization of the basal or agonist independent activity of WT-T2R4 and intracellular alanine mutants. Calcium mobilized (ΔRFU) was normalized to
WT-T2R4 cell surface expression as determined by ELISA. The results were analyzed using one way ANOVA with Tukey's post hoc test, at signiﬁcance level p b 0.05. B. Basal or agonist
independent IP3 accumulation is represented (bar plots) by normalizing to cell surface expression determined by ELISA. Results are from three independent experiments performed in
triplicate. The results were analyzed using Student t-test at a signiﬁcance level p b 0.05. C. Effect of receptor density on basal calcium mobilization. The H214A, Q216A, V234A and
M237A mutants displayed true constitutive activity. The slope values of the constitutively active mutants (CAMs) are shown next to the mutant. The H214A (2.35 ± 1.06) displayed
the highest constitutive activity, with greater than 10-fold increase in basal activity over WT-T2R4 (0.19 ± 0.05).
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a major rearrangement at the cytoplasmic ends of TM5 and TM6
(see Discussion).
4. Discussion
In GPCRs, important structural and sequence differences within re-
ceptors from different classes suggest distinct activation mechanisms.
One of the earliest reported biophysical studies directed at under-
standing the conformational changes in GPCRs was that of rhodopsin.
Site-directed spin label studies on rhodopsin suggested the ‘helixmove-
ment model’ of GPCR activation, which showed that, upon receptor ac-
tivation, TM6 moved away from the 7-TM bundle [19]. This study was
corroborated more than a decade later by crystal structures of the inac-
tive and active states of various Class AGPCRs. In class AGPCRs, compar-
ison of the recent crystal structures of agonist-bound active states of
rhodopsin [20], the β2 adrenergic receptor (β2AR) [21], and the A2A
adenosine receptor (A2AAR) [22], shows that activation of these GPCRs
results in rearrangements of TM5 and TM6. However, the extent of
this conformational change varies. For example, depending on whether
stabilizers of the active conformation were used, such as C-terminal
peptide of the transducin in case of rhodopsin, or conformationally se-
lective nanobody in case of β2AR or none in case of A2AAR, movement
of the cytoplasmic side of TM6 ranges between 3 Å in A2AAR to 8 Å in
β2AR [23]. The Arg of the D/ERY motif in TM3 of most Class A GPCRsmakes an ionic interaction with a conserved acidic residue (D/E) of
TM6. This lock stabilizes the inactive state of many class A GPCRs. How-
ever, D/ERY motif is not found in GPCRs from other classes.
The Class C and Class F GPCRs show divergence from Class A in both
amino acid sequence and pharmacological properties [10,24]. The Class
C GPCRs predominantly include the metabotropic glutamate receptors
(mGluRs),γ-aminobutyric acid (GABA) receptors and the T1Rs. A repre-
sentative structure of a Class C GPCR is still not available. Recently
the structure of a non-Class A GPCR, the smoothened (SMO) receptor,
which belongs to Class F was elucidated [25]. This structure of the SMO
receptor bound to a small antagonist molecule reveals an unusually
complex arrangement of long extracellular loops stabilized by four di-
sulphide bonds. Despite the overall structural conservation of the 7-TM
fold with the Class A GPCRs, the structure of the SMO receptor reveals
many unique features. Most importantly TM5, TM6 and TM7, of the
SMO receptor lack the highly conserved prolines (P5.50, P6.50 and P7.50)
[26], which play pivotal roles in Class A GPCR activation. It seems, even
in the absence of the conserved Class A GPCRs motifs, including D/ERY
in TM3, CWxP in TM6 and NPxxY in TM7 in Class F GPCRs, there are
some common structural features among the different GPCR classes
which stabilize the inactive state.
Recent molecular modeling studies using BiHelix and SuperBiHelix
Monte Carlo methods on T2R38 predicted the hydrogen bond interac-
tions between TM3 and TM6 or between TM5 and TM6 to play a role
in receptor activation [27]. Results from our studies suggest that the
Fig. 4. Homology models of the inactive (red) and constitutively active (yellow) T2R4 were built using the rhodopsin inactive (PDB ID: 1U19) and CAM (PDB ID: 2X72) structures as
templates. A. The left panel shows the intracellular view (from the cytoplasmic side) of TM2–TM3–TM5–TM6 arrangement in both the T2R4 structures. The intracellular loops (ICLs),
along with the location of the ICL3 CAMs, are shown as threads. B. The right panel shows the membrane view of TM5–TM6, along with ICL3 CAMs and the packing interactions of the
LxxSL motif on TM5. In the T2R4 CAM model, the cytoplasmic end of TM6 moves by around 2 Å towards the helical core.
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served in the movement of TM5. Previously, we have reported that
the highly conserved LxxSL motif in T2R1 has an important structural
role in stabilizing the helical conformation of TM5 [11]. Results from
this study suggest that residues of the LxxSL motif also perform a func-
tional role by forming a network of hydrogen-bond interactions with
residues present in ICL3 and TM6, including the highly conserved
His214 (96% conserved in T2Rs). Therefore, the conserved LxxSL motif
at the cytoplasmic end of TM5 plays both a structural and functional
role in T2Rs. In the inactive T2R4 model, Leu207 and Ser210 of the
LxxSL interact with Met237 and His214 respectively. In the CAM
model, His214 interacts with the side chain of Ser210 and backbone of
Leu211, while the side chain of Met237moves away from Lue207 to in-
teract with Leu211 (Supplementary Fig. 1). Unfortunately, our molecu-
lar models gave limited insights into the interactions of the ICL3
residues; this can be due to a number of factors. For example, it is well
known that loops are the most ﬂexible regions in GPCRs and predicting
the conformation of the loop is very difﬁcult. In addition, the binding of
intracellular proteins including G-protein(s), on the intracellular side of
T2Rs, might cause conformational changes in the ICLs, which cannot be
predicted by the molecular models.
There is a dearth of ligands with good efﬁcacy for T2R4. Previously,
T2R4 was shown to be activated by 15 bitter compounds, with only
the arbitrary threshold values for activation reported, except for colchi-
cine [28]. We tested the pharmacology proﬁle of four of those ligands;
quinine, denatonium benzoate, colchicine and yohimbine and found
only two of them activating T2R4 (data not shown). Denatonium
benzoate and quinine activate T2R4 with EC50 values of 23 mM and
1 mM respectively [18]. Whereas, colchicine and yohimbine were un-
able to show any signiﬁcant activation of the receptor in our assay con-
ditions. In this study, there were a number of mutants, which showed
no detectable signal, or the signal was not saturated even with 5 mM
quinine and few mutants showed high EC50 values. We speculate thatthe conformational changes in the receptor brought about by thesemu-
tations might have altered the ligand binding pocket, thereby affecting
quinine binding. It is possible that the signal might be rescued when
induced with a different ligand. However, in the absence of other
well-characterized agonists and antagonists of T2R4, this aspect could
not be pursued further. Similarly, for the mutants that showed high
EC50 mutant/wild type ratio, whether this loss in function resulted be-
cause of altered receptor activation and/or defective ligand binding,
could not be characterized for now.
5. Conclusions
Our results show that the network of interactions involving con-
served residues at the cytoplasmic ends of TM5 and TM6 play an im-
portant role in stabilizing the inactive state of T2Rs. Changes in this
network, brought about by mutations such as H214A, lead the receptor
to adopt an active conformation which involves the movement of TM6.
The H214A mutant shows constitutive activity of up to 10-fold over
WT-T2R4 based on slope values determined by calculating the effect
of receptor density on calciummobilization, one of the highest reported
for a GPCR mutant. This study opens up new areas of research on bitter
taste signaling. Development of assays for the CAMs identiﬁed in this
study would allow pharmacological characterization of novel bitter
taste blockers into antagonists and inverse agonists.
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